⌕
Hims & Hers Health · HIMS · NYSE
Tenet 26 · Weak
Compare
$18.88−4.28%Market openTenet 26 · Weak
$18.88−0.85 (−4.28%)
Market open · 15-min delayed · as of 1:49 PM ET· NYSE · USD

Hims & Hers Health (HIMS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is HIMS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● The Motley FoolNov 16, 2026 · 13:36 ET
Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?

Hims & Hers Health grew its revenue by 49% last quarter. The company incurred a loss, however, as its gross margins deteriorated.…

HIMS −4.3% todayRead at source ↗
● The Motley FoolNov 14, 2026 · 08:00 ET
Why Is Hims Stock Crashing, and is it a Buying Opportunity?

Revenue is increasing, but so are its operating expenses.…

HIMS −4.3% todayRead at source ↗
● Defense WorldNov 14, 2026 · 03:34 ET
Hims & Hers Health, Inc. $HIMS Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC reduced its position in shares of Hims and Hers Health, Inc. (NYSE: HIMS) by 16.1% during a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commis…

HIMS −4.3% todayRead at source ↗
● The Motley FoolNov 13, 2026 · 12:40 ET
Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?

Hims & Hers stock is facing margin pressure as it increases sales of branded weight-loss drugs and expands internationally. The company has a big opportunity in the peptide market.…

HIMS −4.3% todayRead at source ↗
● Zacks Investment ResearchNov 13, 2026 · 12:16 ET
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs

Hims & Hers unites with Lilly to offer FDA-approved weight-loss drugs, Zepbound and Foundayo, expanding patient access and strengthening its obesity care platform.…

HIMS −4.3% todayRead at source ↗
● Zacks Investment ResearchNov 13, 2026 · 10:01 ET
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.…

HIMS −4.3% todayRead at source ↗
● MarketBeatNov 12, 2026 · 08:22 ET
Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off

Even a nearly 9% rebound on Wednesday, Nov. 11, couldn't undo a punishing start to the week for Hims & Hers Health NYSE: HIMS. Shares had already plunged nearly 12% ahead of Monday evening's Q3 earnings report, and disap…

HIMS −4.3% todayRead at source ↗
● Seeking AlphaNov 11, 2026 · 14:25 ET
Hims & Hers: Three Big Sacrifices

Hims & Hers Health missed Q3 estimates, subscribers fell QoQ, and gross margin declined to a new low. To make matters worse, the company issued weak Q4 and FY2026 guidance. But most of the damage was intentional to set u…

HIMS −4.3% todayRead at source ↗
● Zacks Investment ResearchNov 11, 2026 · 13:40 ET
Hims & Hers Q3 Earnings Miss Estimates, Gross Margin Down

HIMS shares dip nearly 3% after Q3 earnings and revenue miss, a sharp gross margin contraction and lower 2026 adjusted EBITDA guidance.…

HIMS −4.3% todayRead at source ↗
● Seeking AlphaNov 11, 2026 · 13:39 ET
Hims & Hers Health: The Thesis Is Getting Shaky (Rating Downgrade)

I'm downgrading Hims & Hers Health, Inc. to Hold, as Q3 raised more questions than it answered. Revenue grew 49% to $890M, but excluding Eucalyptus, growth was about 26%, and subscribers fell 100K sequentially. Gross mar…

HIMS −4.3% todayRead at source ↗
● 247 WallstNov 11, 2026 · 12:55 ET
Hims & Hers Climbs 6% Despite Five States Joining FTC Suit; Eli Lilly Dips, Novo Nordisk Holds Steady

Hims and Hers is bouncing back after a brutal selloff, yet the legal heat keeps rising and its two biggest drug suppliers are sitting out the rally. What does the market see that the lawsuit headlines don't?…

HIMS −4.3% todayRead at source ↗
● BenzingaNov 11, 2026 · 09:16 ET
Hims & Hers Week in Review: Q3 Miss, Weak Q4 Outlook, Huberman Joins Board

Hims & Hers Health Inc. (NYSE:HIMS) had a busy week that included third-quarter results that missed estimates, a new board member in Andrew Huberman and a round of analyst price target changes.…

HIMS −4.3% todayRead at source ↗
● Zacks Investment ResearchNov 10, 2026 · 16:21 ET
HIMS Q3 Earnings Call Highlights Marketing Reset and Margin Pressure

Hims & Hers shifts focus on weight-loss expansion and international growth as Q3 margin pressure, subscriber losses and reduced profit guidance cloud its near-term outlook.…

HIMS −4.3% todayRead at source ↗
● Seeking AlphaNov 10, 2026 · 15:36 ET
Hims & Hers Health: Don't Nitpick Quarterly Results

Hims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. HIMS strategically reduced marketing spend to prepare for the Eli Lilly GLP-1 partnership, intern…

HIMS −4.3% todayRead at source ↗
● BenzingaNov 10, 2026 · 13:54 ET
Weight-Loss Reset Dents Hims & Hers Outlook, But Analyst Sees Opportunity

Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after the company reported worse-than-expected third-quarter financial results and trimmed guidance on Monday.…

HIMS −4.3% todayRead at source ↗
● 24/7 Wall StreetNov 10, 2026 · 13:52 ET
Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady

A surprise quarterly loss and a weaker profit outlook are hitting Hims & Hers (NYSE:HIMS) hard. Hims & Hers stock was last at $18.77, down 18%.…

HIMS −4.3% todayRead at source ↗
● Schaeffers ResearchNov 10, 2026 · 13:35 ET
4 Post-Earnings Losers Drawing Unusual Options Volume

Several stocks are seeing unusual options activity following their latest earnings reports, with Hims & Hers Health Inc (NYSE:HIMS), GeneDx Holdings Corp (NASDAQ:WGS), Groupon Inc (NASDAQ:GRPN), and Digital Turbine Inc (…

HIMS −4.3% todayRead at source ↗
● 24/7 Wall StreetNov 10, 2026 · 13:03 ET
Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week

Shares of Hims & Hers (NYSE:HIMS) traded at $18.76 at midday Tuesday. That is 18.22% lower on the session and 25.67% lower over the past week.…

HIMS −4.3% todayRead at source ↗
● Schwab NetworkNov 10, 2026 · 11:30 ET
HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus

Marley Kayden crunches the numbers on Hims & Hers (HIMS) earnings and its worse-than-expected revenue growth. The stock plunged following the opening bell as investors question the telehealth company's guidance.…

HIMS −4.3% todayRead at source ↗
● Seeking AlphaNov 10, 2026 · 09:30 ET
Hims & Hers: Why I'm Not Buying Back Yet (Rating Downgrade)

Hims & Hers grew Q3 revenue 49% to $890.4 million, but adjusted EBITDA increased just $4 million to $82.4 million. Gross margin contracted from 73.8% to 57.2%, while subscribers declined 100,000 sequentially despite risi…

HIMS −4.3% todayRead at source ↗
● BenzingaNov 10, 2026 · 08:16 ET
Hims & Hers Stock Feels a Pinch Tuesday: What's Happening?

Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after the company reported worse-than-expected third-quarter financial results Monday after the market closed. Also, Needham maintained a Buy rating on…

HIMS −4.3% todayRead at source ↗
● 24/7 Wall StreetNov 10, 2026 · 07:25 ET
Hims & Hers Just Warned Investors for the Third Time This Year. CEO Andrew Dudum Calls the Subscriber Losses a Trade He'll Make ‘Every Time'

Hims & Hers cut its 2026 adjusted EBITDA outlook for the third time this year, to $257 million to $277 million from February's $300 million to $375 million, posted a surprise $33 million loss, and CEO Andrew Dudum called…

HIMS −4.3% todayRead at source ↗
● The Motley FoolNov 10, 2026 · 07:01 ET
Hims & Hers: 3 Key Takeaways for Long-Term Investors

Revenue grew 49% year-over-year to $890 million in the third quarter. Subscribers reached 2.8 million despite a 100,000 net subscriber decline.…

HIMS −4.3% todayRead at source ↗
● BarronsNov 10, 2026 · 06:24 ET
Nvidia, Hims & Hers, JBS, Take-Two, and More Stocks That Explain Today's Market

Hims extends a recent slump after a third-quarter loss, while JBS sinks as Chinese beef import quotas hit the meatpacking business.…

HIMS −4.3% todayRead at source ↗
● Business WireNov 9, 2026 · 16:05 ET
Dr. Andrew Huberman Joins Hims & Hers Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, announced the appointment of Andrew Huberman, Ph.D., to the company's Board of Direct…

HIMS −4.3% todayRead at source ↗
● Business WireNov 9, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended Septem…

HIMS −4.3% todayRead at source ↗
● PRNewsWireNov 6, 2026 · 06:47 ET
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYS…

HIMS −4.3% todayRead at source ↗
● Business WireNov 5, 2026 · 09:00 ET
Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced four new partners joining Hims & Hers Benefits: Grüns®, Medjet®, Tonal™, and Viome™. The pr…

HIMS −4.3% todayRead at source ↗
● PRNewsWireNov 2, 2026 · 17:54 ET
HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit

NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both date…

HIMS −4.3% todayRead at source ↗
● Newsfile CorpNov 2, 2026 · 15:15 ET
HIMS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS

New York, New York--(Newsfile Corp. - November 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July …

HIMS −4.3% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 12:59 ET
Hims & Hers Health, Inc. (NYSE:HIMS) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Hims & Hers Health, Inc. Securities Lawsuit - Contact Portnoy Law Firm

LOS ANGELES, Nov. 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies investors in Hims & Hers Health, Inc. (NYSE: HIMS) that a securities class action lawsuit has been filed on behalf of shareholders who purchase…

HIMS −4.3% todayRead at source ↗
● Business WireNov 2, 2026 · 11:56 ET
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Hims (NYSE: HIMS) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

NEW YORK--(BUSINESS WIRE)---- $HIMS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims” or the “Company”) (NYSE: HIMS) an…

HIMS −4.3% todayRead at source ↗
● Business WireNov 2, 2026 · 11:01 ET
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law.…

HIMS −4.3% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA15−4.3%
UBS4−1.3%
INTC3−7.4%

Article counts from the last market-wide feed page, across every symbol we track and not just HIMS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.